Guj. Themis Bio. Q1 FY27 Results (NSE: GUJTHEM)

· Analysis by Alpha Inflection

Signal: Margin pressure

The read

The quarter shows a YoY growth-versus-margin trade-off: revenue rose 22.07% to ₹4,379.00 lakh and PAT rose 22.06% to ₹1,106.67 lakh, but EBITDA margin fell 109bps to 47.79% as employee cost rose 51.72% and depreciation rose 34.72%; the 1.00% QoQ revenue decline makes the next quarter important for confirming whether the margin pressure is temporary.

Guj. Themis Bio. Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹43.79 Cr+22.07%-1.00%
EBIT₹16.95 Cr+24.78%
Net profit₹11.07 Cr+22.06%
EPS₹1.02+22.89%
EBIT margin47.79%

P&L walk

Consolidated revenue grew 22.07% YoY to ₹4,379.00 lakh, but EBITDA grew slower at 19.34% and margin fell 109bps to 47.79% as employee costs rose 51.72% YoY and depreciation rose 34.72%; PAT still increased 22.06% to ₹1,106.67 lakh because finance cost and other income were not major incremental drags.

Segments

The company reports one business segment—manufacturing of fermentation-based pharmaceutical intermediates and APIs—and consolidated results are identical to standalone because the two new overseas subsidiaries contributed nil revenue and nil profit.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.